Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: Treatment implications based on a real-world Canadian population

RMD Open

Volumn 1, Issue 1, 2015, Pages

  Haraoui, Boulos ^a   Jovaisas, Algis ^b   Bensen, William G ^c   Faraawi, Rafat ^c   Kelsall, John ^d   Dixit, Sanjay ^c   Rodrigues, Jude ^e   Sheriff, Maqbool ^f   Rampakakis, Emmanouil ^g   Sampalis, John S ^g   Lehman, Allen J ^h   Otawa, Susan ^h   Nantel, Francois ^h   Shawi, May ^h  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d Mary Pack Arthritis Centre   (Canada)

^e Clinical Research and Arthritis Centre   (Canada)

^f Nanaimo Regional General Hospital   (Colombia)

^g Scientific Affairs   (Canada)

^h Janssen Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018193043     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2015-000078     Document Type: Article

References (24)

1. Caplan L, Wolfe F, Russell AS, et al. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 2007;34:696-705.
2. Hoes JN, Jacobs JW, Buttgereit F, et al. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 2010;6:693-702.
3. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:628-34.
4. Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008;59:1074-81.
5. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
6. Curtis JR, Yang S, Patkar NM, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014;66:990-7.
7. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33.
8. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007;56:1754-64.
9. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011;306:2331-9.
10. Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-93.
11. Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 2012;39:1559-82.
12. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
13. McKeown E, Bykerk VP, De LF, et al. Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort. Rheumatology (Oxford) 2012;51:1662-9.
14. Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012;71:1128-33.
15. vina-Zubieta JA, Abrahamowicz M, De Vera MA, et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford) 2013;52:68-75.
16. Public Health Agency of Canada. Life with Arthritis in Canada: A personal and public health challenge. 2010. http://www.phac-aspc. gc.ca/cd-mc/arthritis-arthrite/lwaic-vaaac-10/pdf/arthritis-2010-eng. pdf (accessed Nov 2014).
17. Thorne C, Bensen WG, Choquette D, et al. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry. Arthritis Care Res (Hoboken) 2014;66:1142-51.
18. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011;70:1914-20.
19. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
20. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.
21. Caplan L, Russell AS, Wolfe F. Steroids for rheumatoid arthritis: the honeymoon revisited (once again). J Rheumatol 2005;32:1863-5.
22. Thomas E, Symmons DP, Brewster DH, et al. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol 2003;30:958-65.
23. Sihvonen S, Korpela M, Laippala P, et al. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol 2004;33:221-7.
24. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.